|

NEOSENT: Early Anti-PD-1 Therapy In High-Risk Stage II Melanoma

RECRUITINGSponsored by AC Camargo Cancer Center
Actively Recruiting
SponsorAC Camargo Cancer Center
Started2025-04-23
Est. completion2027-05
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07680699

Summary

This is an observational cohort study evaluating clinical and pathological outcomes in patients with high-risk stage II melanoma. Patients are included after receiving treatment as part of routine clinical practice. Decisions about treatment, including whether to start anti-PD1 therapy before surgery, are made by the treating physician and are not influenced by the study. The study compares outcomes between patients who started anti-PD1 therapy before surgery and those treated according to the usual timing in clinical practice. No treatments are assigned as part of the study.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

\- Adults (≥18 years) with histologically confirmed cutaneous melanoma stage IIB or IIC or stage III (N1c), managed in routine clinical practice.

Exclusion Criteria:

* Patients without sufficient clinical or follow-up data.
* Patients who do not provide informed consent (for prospective cohort).

Conditions2

CancerCutaneous Melanoma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.